We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis.
The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over 36 months of treatment: PURE Study‘ was presented at the AAD VMX, 23-25 April 2021.
- What have we learned about the clinical utility of secukinumab in the treatment of psoriasis and what questions remain unanswered? (0:20)
- Could you tell us a little about the rationale, objectives, design and inclusion criteria of the PURE registry? (1:19)
- What was the impact of secukinumab in Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores over 36 months in patients with plaque psoriasis? (3:33)
- What other outcomes were reported in this study? (5:21)
- What future studies are planned within the PURE registry? (7:48)
Disclosures: KAP has served as a consultant, speaker, clinical researcher, scientific officer, steering committee member, or advisor for AbbVie, Akros, Amgen, Anacor, Arcutis, Astellas, Avillion, Bausch Health/Valeant, Baxalta, Boehringer Ingelheim, Bristol-Myers Squibb, Can-Fite Biopharma, Celgene, Coherus, Dermavant, Dermira, Dice Pharmacueticals, Dow Pharma, Eli Lilly, Evelo, Galapagos, Galderma, Genentech, Gilead, GSK, Incyte, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Meiji Seika Pharma, Merck (MSD), Merck- Serono, Mitsubishi Pharma, Moberg Pharma, Novartis, Pfizer, PRCL Research, Regeneron, Roche, Sanofi-Aventis/Genzyme, Sun Pharma, Takeda, UCB and Xencor.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the AAD VMX 2021.
Share this Video
Related Videos In Psoriasis
Andy Blauvelt, EADV 2021: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis
touchIMMUNOLOGY had the pleasure of speaking with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the oral TYK2 inhibitor, deucravacitinib, and how it compared to placebo and apremilast in the treatment of scalp psoriasis. His presentation entitled ‘Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Scalp […]
Leon Kircik, AAD VMX 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis. His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A […]
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!